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Peri-interventional hemostasis is an increasingly important area 
of research. However, only scarce knowledge on the relationship 
between thromboelastometry or thromboelastography and conven-
tional parameters of hemostasis exists [2]. Thus, it is important to 
research such relationships; new research presented here shows that 
factor XIII, alone and in combination with other parameters, has a 
frequent and profound effect on postoperative clot firmness [3]. 
Early intervention (and therefore fast to immediate availability 
of procoagulant products) is an important mainstay to avoid the 
vicious cycle of perioperative coagulopathy; this is the very practi-
cal reason why the experiments for fast thawing devices reported 
here are important [4]. 
‘New’ (NOACs) or 'direct' oral anticoagulants (DOACs) are 
continuing to seize their increasing share of indications for an-
tithrombotic therapy. As these patients will also be in increasing 
need for surgery or other interventions, reliable point-of-care test-
ing to exclude or suggest the presence of NOACs (or DOACs) in 
the peri-interventional setting is therefore a requirement; such a 
methodology is reported for the one oral thrombin inhibitor on the 
market [5].
Overall, hemostasis issues in various facets are becoming increas-
ingly important in current medical practice, especially in patients 
that might develop a need for hemotherapy. This is why we believe 
that this issue is of special interest for a diversified audience.
The current issue of Transfusion Medicine and Hemo-
therapy is dedicated to various hemostasis aspects that will influ-
ence hemotherapy in one way or the other. We believe that this is 
timely, as hemostasis management has made its way from a highly 
specialized topic worked upon by a relative small group of expert 
care givers and technicians to a topic that is widely recognized to 
have increasingly broad and major clinical impact, dealt with by an 
increasingly less specialized group of users. Thus, this area nowa-
days receives increasingly broad attention. The fascination of he-
mostasis management, however, is unbroken. In order to provide 
optimal patient care, it is of utmost importance to continuously 
expand our knowledge on physiology, pathophysiology, optimal 
usage of technical equipment, therapeutic products, and treatment 
processes.
The articles of this special topic attempt to give insights into dif-
ferent aspects of various parts of modern hemostasis pathophysiol-
ogy and hemostasis management; they might be considered repre-
sentative for various aspects of hemostasis (management) and thus 
might be helpful in various hemotherapeutic treatment decisions.
The discussion of potential thromboembolism in patients with 
inherited fibrinogen disorders is an example of a (potentially seri-
ous) side effect in hypocoagulable patients, where the use of proco-
agulant treatment options might lead to clinically relevant hyper-
coagulability [1]. 
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